Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

NCT05997056 is registered in ClinicalTrials.gov with Aadi Bioscience, Inc. as lead sponsor.

NCT NCT05997056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05997056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multi-center, Open-label, Single Arm Study of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors
Lead sponsor
Aadi Bioscience, Inc.
Phase
Phase 2
Overall status
Completed
Start date
October 20, 2023
Completion date
October 3, 2025
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

gastrointestinal neuroendocrine tumor, net, neuroendocrine tumors, pancreatic neuroendocrine tumor, pulmonary neuroendocrine tumor